DOCSLIB.ORG

0202 Vey Pres Mabs En Onco-Hemato Monaco Fev2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
0202 Vey Pres Mabs En Onco-Hemato Monaco Fev2018 Les anticorps monoclonaux dans tous leurs états: Des avancées dans le traitement des hémopathies malignes Norbert Vey Beirao et al. TVJ 2016 Delivery Systems for Immunotherapy mAb BITE α-CD3 single- Linker chain Ab α-CDxx Ab V H VL Ac. Immuno-conjugués (ADC) • 4 ADC enregistrés • Un boom depuis 2013 • 30 ADC en développement clinique en oncologie Beck et al. Nat Rev. 2017 Gemtuzumab ozogamycin in the frontline therapy of AML (FDA re-approved 2017) H. Dombret. EHA 2012 Educational Book Safety issues: Safety issues: - -MyelosuppressionMyelosuppression - -Hepatic Hepatic toxtox/SOS/SOS Hills, R et al., Lancet Oncol 2014 Brentuximab Vedotin: an anti-CD30 MMAE antibody drug conjugate FDA and EMEA approved for CD30+ refractory/relapsed Hodgin Lymphoma and Anaplastic Large cell NHL Brentuximab Vedotin in refractory/relapsed Hodgkin Lymphoma OS following treatment with brentuximab vedotin. Ajay K. Gopal et al. Blood 2015;125:1236-1243 ©2015 by American Society of Hematology Anti-CD22 immunoconjugué: Inotuzumab ozogamycine dans les LAL Inotuzumab phase III (INO-VATE) BCP-ALL, R/R Kantarjian, N Engl J Med. 2016 Aug 25;375(8):740-53 Inotuzumab phase III (INO-VATE) BCP-ALL, R/R Duration of remission Overall Survival Progression-free Survival Kantarjian, N Engl J Med. 2016 Aug 25;375(8):740-53 Comment progresser? Les points critiques Choix de la cible Choix du linker Choix du cytotoxique Caractéristiques d’une cible idéale (Ag) • Expression large dans la pathologied’intérêt • Spécificité • Accessibilité • Internalisée (pas obligatoire/ effet “by-stander”) • Expression dans le compartiment souche L’efficacité de l’Ac non conjugué correspondant n’est pas indispensable (exemple du Brentuximab) Caractéristiques du linker et du payload idéal • Linker – Stable dans le sang – Hydrolysable dans la cellule – Ratio ADC/Ac non conjugué élevé • Payload – Activité cytotoxique +++ (pMol) – Hydrophilie – Échappement aux pompes à efflux – Disponibilitéd’une “poignée chimique” ADCs in clinical development (MMAE only) Beck et al. Nat Rev. 2017 Les anticorps bispécifiques: des applications multiples Kontermann & Brikmann, Drug Discov. Today, 2015 Diversité des formats d’Ac bispécifiques Kontermann & Brikmann, Drug Discov. Today, 2015 Blinatunomab: CD19xCD3 bispecific T-cell engager Blinatumomab phase III (TOWER) LAL-B, R/R, molecular response Topp M et al., EHA 2016 Blinatumomab phase III (TOWER) Overall Survival (Intent-to-Treat) Topp M et al., EHA 2016 Flotetuzumab CD123 x CD3 Bispecific DART Protein “Anti-CD123” Anti-CD3 • DART bispecific platform – Multiple applications across different diseases – Predictable manufacturability – Long-term stability – Ability to tailor half-life and valency CD123 x CD3 DART • Optimal variable light and heavy chain pairing allows for • Activation Target Tumor tighter conformation and closer proximity between effector T Cell • Cytokine release Cell Cell • Expansion Killing (CD3+) cells and target (CD123+) cells • Differentiation Tumo • Flotetuzumab (MGD006/S80880) mode of action: r Cell redirected T-cell killing of CD123+ cells Root, et al. Antibodies 2016, 5, 6 Chichili, et al. SciTransl Med. 2015 May 27;7(289) 20 Anti-Leukemic Activity at Threshold Dose ≥ 500 ng/kg† Of 14 patients treated with flotetuzumab in dose escalation phase at threshold dose ≥ 500 ng/kg/day who received ≥ one cycle of treatment and had post-treatment bone marrow biopsy TF Treatment Group • Rapid responses after single cycle TF TF Cohort 2: 100à50 0 ng/kg/day of therapy in majority of patients 4 Days On/ Cohort 2a: 30à100à500 ng/kg/day 3 Days Off that respond (cycles ≤ 2) Cohort 3: 30à100à 700ng/kg/day Cohort 7: 30à100à 500ng/kg/day TF 7 Days On Cohort 8: 30à100à 700ng/kg/day • Objective resp. rate TF TF (CR/CRi/MLF/PR): 6/14 pts (43%) AML AML MDS AML AML AML AML AML AML AML AML AML AML AML • CR Rate: 4/14 (28%) (CR/CRi) SD/OB SD/OB Change in BM Blast Count from Baseline (%) PR MLF 1 CRi 1 CRi2 CR 3 CRm 4 CR = Complete Response; CRm = molecular CR; CRi = Complete Response with incomplete hematological improvement; MLF = Morphologic Leukemia-free state; PR = Partial Response; SD/OB = Stable Disease/Other Anti-Leukemic Benefit; PD= Progressive Disease; (Modified ELN 2017 criteria) † Data cut-off Aug. 1, 2017; presented at ESMO 2017 Vey et al. ESMO 201721 Other bispecific mAbs in clinical development Kontermann & Brikmann, Drug Discov. Today, 2015 Delivery Systems for Immunotherapy mAb BITE CART Infusion react. TLS TLS Target-related CNS CRS Constitutional CNS CRS „off-target“ Efficacy Tolerability PD-1 and CTLA-4. Philippe Armand Blood 2015;125:3393-3400 ©2015 by American Society of Hematology Phase IB/II Study of Nivolumab in Combination with Azacytidine in Patients with Relapsed AML (Naval Daver et al. ASH 2016) • Treatment: – AZA 75mg/m2 Days 1-7 with nivolumab 3mg/kg on Day 1 and 14. Courses were repeated approximately every 4-5 • 51 pts with a median age of 69 years (range, 45 – 90) • Efficacy: – 35 pts are evaluable for response: – CR/CRi: 6 (18%)) – HI: 5 (15%) • Tolerance – 4- and 8-wk mortality were 0 and 6% – Grade 3/4 and Grade 2 immune mediated toxicities were observed in 7 (14%) and 6 (12%) ICP blockade clinical trials in AML/MDS Combo Drug Company Drug Phase Patient # Patient Segment(s) LOT NCT M.D. Anderson, Idarubicin+ I/II 75 Patients with AML, MDS 1st line (II) NCT02464657 BMS cytaribine Patients with AML in Remission post- NIH/NCI None* II 80 Maintenance NCT02275533 chemo +/- ipilimumab M.D. Anderson, and or II 120 Patients with various risk MDS 2nd line NCT02530463 BMS Vidaza 6 cohorts nivolumab M.D. Anderson, Patients with AML at high risk for None II 30 Maintenance NCT02532231 BMS relapse M.D. Anderson, Patients With Refractory/ Relapsed Vidaza II 54 2nd line+ NCT02397720 BMS AML Lirilumab +/- 1st line (high M.D. Anderson, nivolumab II 80 Patients with various risk MDS risk); 2nd line NCT02599649 BMS and/or (low risk) Vidaza 4 cohorts Participants with blood cancers (MDS, pembrolizumab Merck None I 156 2nd line+ NCT01953692 MM, HL, MLBCL, NHL, FL, DLBCL) 1st line cohort Patients with intermediate/high/very Atezolizumab Roche +/- Vidaza I 46 and 2nd line NCT02508870 high-risk MDS cohort Subjects With MDS Who Fail to Achieve CC-486 +/- Durvalumab Celgene II 194 an Objective Response to Vidaza or 2nd line NCT02281084 durvalumab Dacogen Anti-KIR phase I in elderly AML • AcMo humanisé IgG4 (Innate Pharma, Marseille, France) NK cell from – lie KIR2DL1-2-3, et S1-2 donor – Bloque liaison KIR à HLA-C Tumor cell • Etude phase 1 d’IPH2101: 23 patients >60 ans en RC1 from transplanted KIR- – MTD non atteinte à 3 mg/kg ligand patient mismatc – EI modérés et transitoires (fièvre, frissons, rash) h • Etude phase 1 du lirilumab (IPH2102): 20 patients multipathologie – MTD non atteinte à 10 mg/kg – EI modérés et transitoires (fièvre, frissons, rash) – Saturation complète des KIR >12 wks à >1 mg/kg Vey et al. Blood 2012 Vey et al. Oncotarget 2017 Romagne, Blood, 2009 EFFIKIR: placebo-controlled randomized study of lirilumab in the maintenance of CR1 AML: Leukemia-Free Survival N=152 P= 0.929 P= 0.144 Vey et al. ASH 2017 Conclusion • Les progrès technologiques ont permis de développer une grande variété de formats d’anticorps • L’efficacité est variable selon les maladies • Un effort majeur est à faire pour évaluer rapidement ces approches • Et surtout, tester leurs combinaisons Activer les cellules T: rationnel pour l’utilisation des anti-PD1/PDL1, anti-CTLA4 CPi clinical trials in AML/MDS Drug Company Combo Drug Phase Patient # Patient Segment(s) LOT NCT Idarubicin+ M.D. Anderson, BMS I/II 75 Patients with AML, MDS 1st line (II) NCT02464657 cytaribine NIH/NCI None* II 80 Patients with AML in Remission post-chemo Maintenance NCT02275533 +/- ipilimumab M.D. Anderson, BMS II 120 Patients with various risk MDS 2nd line NCT02530463 and or Vidaza 6 cohorts nivolumab M.D. Anderson, BMS None II 30 Patients with AML at high risk for relapse Maintenance NCT02532231 M.D. Anderson, BMS Vidaza II 54 Patients With Refractory/ Relapsed AML 2nd line+ NCT02397720 Lirilumab +/- nivolumab 1st line (high risk); M.D. Anderson, BMS II 80 Patients with various risk MDS NCT02599649 and/or Vidaza 2nd line (low risk) 4 cohorts Participants with blood cancers (MDS, MM, HL, pembrolizumab Merck None I 156 2nd line+ NCT01953692 MLBCL, NHL, FL, DLBCL) 1st line cohort Patients with intermediate/high/very high-risk Atezolizumab Roche +/- Vidaza I 46 and 2nd line NCT02508870 MDS cohort CC-486 +/- Subjects With MDS Who Fail to Achieve an Durvalumab Celgene II 194 2nd line NCT02281084 durvalumab Objective Response to Vidaza or Dacogen Anticorps anti-CD20 : RITUXIMAB dans les LAL • CD20+ : 30 à 50% des LAL-B • L’expression du CD20 est associé à un facteur de mauvais pronostic l Etude de phase III (Maury et al., NEJM, 2016) Expression du CD20>20% : ajout de 16-18 perfusions de RITUXIMAB au protocole d’inspiration pédiatrique GRAALL-2005 pour les LAL-B 65 71 % % 64 52 % % Développement des anti-CD20 Singh et al. JCST 2015 Vadastuximab Talirine (SGN-CD33A; 33A) Clinical studies of Vadastuximab Talirine (SGN-CD33A) • Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive AML (Dale L. Bixby et al. Abs 590, ASH 2016): – N=26 pts – 30- and 60-day mortality rates = 0% and 15%. – CR= 23% Cri=31% MLFS= 19% – Tox: myelosuppression • Vadastuximab Talirine Plus Hypomethylating Agents in Frontline Older Patients with AML (Amir T. Fathi et al., Abs 591 ASH 2016): - 53 patients (age 75 years; range, 60- 87) - 33A: 10 mcg/kg, IV every 4 weeks on the last day of HMA - 17 of 36 responders (47%) achieved MRD negativity by flow cytometry Mécanismes de résistance aux ADC • Down-regulation de l’Ag • Augmentation du recyclage à la surface de la cellule • Diminution du trafic intra-cellulaire • Efflux du payload • Absence de pénétration intra-tumorale Ciblage de CD33: exemple des avancées possibles Beck et al.
Load more

Recommended publications
  • Attachement B Summary
    Summary - Paediatric Strategy Forum Medicinal Product Development for Acute Myeloid Leukaemia in Children and Adolescents 24-6-19 Paediatric Strategy Forum for Medicinal Product Development for Acute Myeloid Leukaemia in Children and Adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration 11-12 April 2019 Summary Context: The fourth multi-stakeholder Paediatric Strategy Forum, organised by ACCELERATE in collaboration with the European Medicines Agency (EMA) with participation of the Food and Drug Administration (FDA) was held at Erasmus University, Rotterdam and focused on acute myeloid leukaemia (AML) in children and adolescents. Paediatric Strategy Forums are multi-stakeholder (clinicians, academics, patient advocates, pharmaceutical companies and regulators) scientific meetings on specific topics regarding paediatric oncology. The Forums aim to share information and advance learning, which may inform subsequent strategic and regulatory decisions on the development of medicines for children with cancer. The goal of this meeting was to facilitate development of innovative medicines for the treatment of children and adolescents with AML, and ultimately, by extension, introduce these medicines into the standard-of-care for children. The 5-year overall survival (OS) for paediatric AML currently is approximately 75%; however, the standard of care for frontline therapy for many decades has been daunorubicin and cytarabine. Furthermore, cardiotoxicity, due to anthracyclines, is an important long-term sequelae in a substantial proportion of survivors. AML is more frequent under the age of 3 years and its incidence initially declines and subsequently increases throughout young adulthood and is most frequent in the elderly. The occurrence of specific genetic alterations differs in AML in children compared to adults and the elderly.
    [Show full text]
  • Engineered Technologies and Bioanalysis of Multispecific Antibody Formats
    Journal of Applied Bioanalysis openaccess http://dx.doi.org/10.17145/jab.20.005 REVIEW Engineered Technologies and Bioanalysis of multispecific Antibody Formats Marta Amaral, Soraya Hölper, Christian Lange, Jennifer Jung, Hanno Sjuts, Sandra Weil, Melanie Fischer, Katarina Rado�evi�, Ercole Rao* Sanofi R&D, Biologics Research. *Correspondence: Sanofi-Aventis Deutschland GmbH, R&D, Biologics Research, Industriepark Höchst, H812, 65926 Frankfurt am Main, Germany. Phone: +49 6930515147. Email: [email protected] Citation: Amaral M, Hölper S, Lange C, Jung J, Sjuts H, Weil S, Fischer M, Rado�evic K, Rao E. Engineered Technologies and Bioanalysis of multispecific ABSTRACT antibody formats. J Appl Bioanal 6(1), The idea of designing multispecific antibodies capable of simultaneously 26-51 (2020). engaging two or more epitopes on the same or different antigens was developed more than 50 years ago. However, the molecular complexity of such Editor: molecules may pose significant challenges for their development and clinical Dr. Lin-zhi Chen, Boehringer use. Particularly challenging is to obtain the correctly assembled combination of Ingelheim Pharmaceuticals Inc., different polypeptide chains, which places significant demand on downstream Ridgefield, CT 06877, USA. process development, analytical characterization and control strategy. Here, we review the progress made in protein engineering to force the correct assembly of Received: July 29, 2019. different heavy and light chains, as well as upstream and downstream processes Revised: September 13, 2019. currently applied to control generation of unwanted byproduct species. We Accepted: September 16, 2019. cover in-depth the analytical methods available to characterize such complex molecules, focusing on mispairing analysis and functional characterization.
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • Flotetuzumab: CD123 × CD3 DART Molecule
    ® Breakthrough Biologics, Life-changing Medicines Corporate Update January 6, 2019 Legal Notices The information in this slide deck is current as of January 6, 2019, unless otherwise noted. The information in this slide deck is qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements Any statements in these materials about future expectations, plans and prospects for MacroGenics (“Company”), including statements about the Company’s strategy, future operations, clinical development of the Company’s therapeutic candidates, milestone or opt-in payments from the Company’s collaborators, the Company’s anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words “subject to”, "believe", “anticipate”, “plan”, “expect”, “intend”, “estimate”, “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company’s filings with the Securities and Exchange Commission.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
    ll ( (51) International Patent Classification: (74) Agent: NETTER, Jr., Robert, C. et al.; Dann, Dorf- C07K 16/28 (2006.01) man, Herrell and Skillman, 1601 Market Street, Suite 2400, Philadelphia, PA 19103-2307 (US). (21) International Application Number: PCT/US2020/030354 (81) Designated States (unless otherwise indicated, for every kind of national protection av ailable) . AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 29 April 2020 (29.04.2020) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/840,465 30 April 2019 (30.04.2019) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicants: INSTITUTE FOR CANCER RESEARCH TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER [US/US]; 333 Cottman Av¬ (84) Designated States (unless otherwise indicated, for every enue, Philadelphia, PA 191 11-2497 (US). UNIVERSTIY kind of regional protection available) . ARIPO (BW, GH, OF KANSAS [US/US]; 245 Strong Hall, 1450 Jayhawk GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Boulevard, Lawrence, KS 66045 (US).
    [Show full text]
  • 2018 Medicines in Development for Cancer
    2018 Medicines in Development for Cancer Bladder Cancer Product Name Sponsor Indication Development Phase ABI-009 AADi Bioscience non-muscle invasive bladder cancer Phase I/II (nab-rapamycin/mTOR inhibitor) Los Angeles, CA www.aadibio.com ALT-801 Altor BioScience non-muscle invasive bladder cancer Phase I/II (tumor antigen-specific T-cell Miramar, FL www.altorbioscience.com receptor linked to IL-2) NantKwest Culver City, CA ALT-803 Altor BioScience non-muscle invasive bladder cancer Phase II (IL-15 superagonist protein complex) Miramar, FL (BCG naïve) (Fast Track), www.altorbioscience.com NantKwest non-muscle invasive bladder cancer Culver City, CA (BCG unresponsive) (Fast Track) B-701 BioClin Therapeutics 2L locally advanced or metastatic Phase I/II (anti-FGFR3 mAb) San Ramon, CA bladder cancer www.bioclintherapeutics.com Bavencio® EMD Serono 1L urothelial cancer Phase III avelumab Rockland, MA www.emdserono.com (anti-PD-L1 inhibitor) Pfizer www.pfizer.com New York, NY BC-819 BioCanCell Therapeutics non-muscle invasive bladder cancer Phase II (gene therapy) Cambridge, MA (Fast Track) www.biocancell.com Medicines in Development: Cancer ǀ 2018 1 Bladder Cancer Product Name Sponsor Indication Development Phase Capzola® Spectrum Pharmaceuticals non-muscle invasive bladder cancer application submitted apaziquone Henderson, NV (Fast Track) www.sppirx.com Cavatak® Viralytics bladder cancer (+pembrolizumab) Phase I coxsackievirus Sydney, Australia www.viralytics.com CG0070 Cold Genesys non-muscle invasive bladder cancer Phase II (oncolytic immunotherapy)
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • IMPROVE Patient Outcomes Thursday, Dec
    IMPROVE Patient Outcomes Thursday, Dec. 10, 2020 • Louisville, Ky. Live Virtual Program #LearnACI The 2020–2021 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association. SITC-0720-148 Thank You To Our Supporters The 2020–2021 Advances in Cancer ImmunotherapyTM series is generously supported in part by independent medical education grants from: DOUBLE-PLATINUM AstraZeneca Pharmaceuticals LP Merck & Co., Inc. PLATINUM Bristol Myers Squibb GOLD Amgen SILVER Exelixis, Inc. Table of Contents Letter from the President . 2 Program Details . 3 Program Planners and Faculty . 6 Program Schedule . 7 Disclosure Information . 8 Program Organizers . 11 Presentations Immunotherapy for the Treatment of Skin Cancers Jae Y. Jung, MD, PhD Norton Cancer Institute . 12 Immunotherapy for the Treatment of Lung Cancer Adam Lye, MD Norton Cancer Institute . 39 Immunotherapy for the Treatment of Hematologic Malignancies Joseph Maly, MD Norton Cancer Institute . 65 Immunotherapy for the Treatment of Genitourinary Malignancies Chandler H. Park, MD Norton Cancer Institute . 90 Immunotherapy for the Treatment of Head and Neck Cancers Aaron Spalding, MD, PhD Norton Cancer Institute . 106 Immunotherapy for the Treatment of Additional Solid Tumors: GI Mike Driscoll, MD Norton Cancer Institute . 121 Practical Barriers in Cancer Immunotherapy Treatment Lennea Coombs, MHS, PA-C Norton Cancer Institute . 136 Toxicity Management Laila Agrawal, MD Norton Cancer Institute . 154 What’s Next for Cancer Immunotherapy? Jaspreet S. Grewal, MD, PhD, MPH Norton Cancer Institute . 180 COVID-19 in Cancer Immunotherapy Joseph Flynn, MD, MPH Norton Cancer Institute .
    [Show full text]
  • Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats
    Journal of Clinical Medicine Review Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats Brent A. Williams 1,*, Arjun Law 2, Judit Hunyadkurti 3, Stephanie Desilets 4, Jeffrey V. Leyton 3,5,6 and Armand Keating 1 1 Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada 2 Hans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada 3 Département de Medécine Nucléaire et Radiobiology, Faculté de Medécine et des Sciences de la Santé, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada 4 Service de Hemato-Oncologie, CHUS, Sherbrooke, QC J1H 5N4, Canada 5 Sherbrooke Molecular Imaging Centre, Centre de Recherche du CHUS, Sherbrooke, QC J1H 5N4, Canada 6 Institute de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada * Correspondence: [email protected] Received: 1 July 2019; Accepted: 16 August 2019; Published: 20 August 2019 Abstract: In recent decades, therapy for acute myeloid leukemia (AML) has remained relatively unchanged, with chemotherapy regimens primarily consisting of an induction regimen based on a daunorubicin and cytarabine backbone, followed by consolidation chemotherapy. Patients who are relapsed or refractory can be treated with allogeneic hematopoietic stem-cell transplantation with modest benefits to event-free and overall survival. Other modalities of immunotherapy
    [Show full text]
  • Copyrighted Material
    127 Index Note: Page numbers in italic refer to figures, those in bold refer to tables. 7.1 see NG2 acute mixed phenotype with t(6;9) 52 α (alpha) 39 leukaemia see mixed with t(8;21)(q22;q22.1) 54, γ (gamma) 39 phenotype acute leukaemia 55, 93, 112 δ (delta) 39 acute monoblastic leukaemia, with t(9;11) or other KMT2A ε (epsilon) 39 case 102, 118–119 rearranged 52 κ (kappa) 38 acute monoblastic/monocytic acute promyelocytic leukaemia, λ (lambda) 38 leukaemia 33 with t(15;17)(q24.1;q21.2) μ (mu) 39 acute monocytic leukaemia, 48–52, 54, 93, 112 case 100, 116–118 acute undifferentiated a acute myeloid leukaemia leukaemia (AUL) 62 abbreviations ix–x, 47, 89 (AML) 48 case 108, 123 acute basophilic leukaemia associated with Down’s adult T‐cell leukaemia/ 14, 36, 55 syndrome 28, 55 lymphoma (ATLL) 74, acute lymphoblastic leukaemia with bi‐allelic CEBPA 92, 94, 112, 113 (ALL) 55–62, 90, 111 mutation 55 aggressive NK‐cell see also B‐lineage acute case 98, 115 leukaemia 76, 91, 111 lymphoblastic leukaemia immunophenotyping of alemtuzumab 27, 73 (B‐ALL) acute myeloid leukaemia ALK1 see CD246 case 103, 119–120 and blastic plasmacytoid ALK‐negative anaplastic large minimal residual disease dendritic cell cell lymphoma 75 (MRD) 77–78 neoplasm 53–54 ALK‐positive anaplastic large therapy‐related 103, 119–120 with inv(3) 52 cell lymphoma 75 T‐lineage acute lymphoblasticCOPYRIGHTED with inv(16) 12, 52, MATERIAL53 ALL see acute lymphoblastic leukaemia (T‐ALL) minimal residual disease leukaemia 60–62, 103–104, 119–120 (MRD) 78 AML see acute myeloid acute mast cell leukaemia with mutated NPM1 leukaemia 20, 23 92, 111 anaplastic large cell lymphoma acute megakaryoblastic with mutated RUNX1 55 75, 95, 113 leukaemia 15, 23, 25, 29, with myelodysplasia‐related case 105, 120 30, 53–54, 55 changes 55 angioimmunoblastic T‐cell with t(1;22)(p13.3;q13.1); not otherwise specified 55 lymphoma 74 RBM15‐MKL1 54, 93 with t(1;22) 92 annexin A1 39 Immunophenotyping for Haematologists: Principles and Practice, First Edition.
    [Show full text]